Samsung Biologics Co.,Ltd. (KRX:207940)

Market Cap	86.90T
Revenue (ttm)	5.03T
Net Income (ttm)	1.29T
Shares Out	46.29M
EPS (ttm)	27,778.66
PE Ratio	67.58
Forward PE	45.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	71,186
Open	1,877,331
Previous Close	1,877,331
Day's Range	1,877,331 - 1,877,331
52-Week Range	1,394,545 - 1,944,983
Beta	0.16
RSI	77.16
Earnings Date	Oct 28, 2025

About Samsung Biologics

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, fini...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 4,770
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2024, Samsung Biologics's revenue was 4.55 trillion, an increase of 23.08% compared to the previous year's 3.69 trillion. Earnings were 1.08 trillion, an increase of 26.31%.